Sierra Oncology Inc (SRRA) stock is up 196.64% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives SRRA stock a score of 67 out of a possible 100.
That rank is primarily influenced by a short-term technical score of 100. SRRA's rank also includes a long-term technical score of 100. The fundamental score for SRRA is 0. In addition to the average rating from Wall Street analysts, SRRA stock has a mean target price of $45.20. This means analysts expect the stock to fall 17.46% over the next 12 months. SRRA has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on SRRA!